Response rates in evaluable patients with CLL/SLL in part 2
| Best response, n (%) [95% CI] . | Treatment-naive, n = 22 . | Relapsed or refractory, n = 56 . | Total, N = 78 . |
|---|---|---|---|
| ORR | 22 (100) [84.56-100] | 53 (94.6) [85.13-98.88] | 75 (96.2) [89.17-99.2] |
| CR | 1 (4.5) | 1 (1.8) | 2 (2.6) |
| PR | 18 (81.8) | 45 (80.4) | 63 (80.8) |
| PR-L | 3 (13.6) | 7 (12.5) | 10 (12.8) |
| SD | 0 | 2 (3.6) | 2 (2.6) |
| PD | 0 | 0 | 0 |
| Missing/not evaluable | 0 | 1 (1.8) | 1 (1.3) |
| Best response, n (%) [95% CI] . | Treatment-naive, n = 22 . | Relapsed or refractory, n = 56 . | Total, N = 78 . |
|---|---|---|---|
| ORR | 22 (100) [84.56-100] | 53 (94.6) [85.13-98.88] | 75 (96.2) [89.17-99.2] |
| CR | 1 (4.5) | 1 (1.8) | 2 (2.6) |
| PR | 18 (81.8) | 45 (80.4) | 63 (80.8) |
| PR-L | 3 (13.6) | 7 (12.5) | 10 (12.8) |
| SD | 0 | 2 (3.6) | 2 (2.6) |
| PD | 0 | 0 | 0 |
| Missing/not evaluable | 0 | 1 (1.8) | 1 (1.3) |
Sixteen patients were not included because the first protocol-specified response assessment time point of 3 months from treatment start date had not been reached and progression had not been observed.
PD, progressive disease; SD, stable disease.